Literature DB >> 9610695

The prognostic significance of the biomarkers p21WAF1/CIP1, p53, and bcl-2 in laryngeal squamous cell carcinoma.

Y T Jin1, S Kayser, B L Kemp, N G Ordonez, S L Tucker, G L Clayman, H Goepfert, M A Luna, J G Batsakis, A K El-Naggar.   

Abstract

BACKGROUND: The clinical course of laryngeal squamous cell carcinoma (LSCC) varies considerably among patients. New biologic markers are needed to facilitate the stratification of individual patients within the conventional clinicopathologic stages of LSCC.
METHODS: Eighty-three LSCCs from an equal number of patients who received at least 10 years of follow-up were investigated for p53, p21WAF1/CIP1, and bcl-2 protein expression by immunohistochemical techniques. The results were correlated with various clinicopathologic parameters, DNA content, and patient outcome by univariate and multivariate statistical analyses.
RESULTS: Stage IV disease, large tumor size (>3 cm), positive lymph node status, extranodal extension, and p53 overexpression (in > 75% of cells) correlated significantly with prognosis in univariate analysis. There was no correlation between patient outcome and age, gender, race, histologic differentiation, or expression of bcl-2 or p21WAF1/CIP1. In multivariate analysis, lymph node status and p53 overexpression were the only factors significantly associated with survival.
CONCLUSIONS: High p53 expression and positive lymph node status were independent predictors of the outcomes of patients with LSCC. These factors may assist in prognostication and better classification of patients for treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9610695

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

1.  Impact of gender on survival in patients with laryngeal squamous cell carcinoma: a propensity score matching analysis.

Authors:  Na Wang; Hong Lv; Ming Huang
Journal:  Int J Clin Exp Pathol       Date:  2020-03-01

2.  MiR-34c induces apoptosis and inhibits the viability of M4e cells by targeting BCL2.

Authors:  Rui Li; Hongxia Zhang; Xiling Zheng
Journal:  Oncol Lett       Date:  2017-12-19       Impact factor: 2.967

Review 3.  Molecular changes in the multistage pathogenesis of head and neck cancer.

Authors:  Brian J Park; Simion I Chiosea; Jennifer R Grandis
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

4.  The role of tumor size and patient's age as prognostic factors in laryngeal cancer.

Authors:  K Markou; J Goudakos; S Triaridis; J Konstantinidis; V Vital; A Nikolaou
Journal:  Hippokratia       Date:  2011-01       Impact factor: 0.471

5.  Prognostic value of telomerase and DNA ploidy in laryngeal carcinoma.

Authors:  Talaat El Samny; Hisham El Halaby; Lobna El Fiky; Mohamed Nassar; Ali El Makhzangy; Sannaa Eissa
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-03-01       Impact factor: 2.503

6.  Clinical and molecular prognostic factors in operable laryngeal cancer.

Authors:  Konstantinos Vlachtsis; Angelos Nikolaou; Konstantinos Markou; George Fountzilas; Ioannis Daniilidis
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-03-01       Impact factor: 2.503

7.  Intense p53 staining is a valuable prognostic indicator for poor prognosis in medulloblastoma/central nervous system primitive neuroectodermal tumors.

Authors:  R T Woodburn; B Azzarelli; J F Montebello; I E Goss
Journal:  J Neurooncol       Date:  2001-03       Impact factor: 4.130

Review 8.  Clinical implications of biomarkers in head and neck cancer.

Authors:  W M Koch
Journal:  Curr Oncol Rep       Date:  1999       Impact factor: 5.075

Review 9.  Molecular pathogenesis of head and neck squamous cell carcinoma.

Authors:  David Hardisson
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-05-08       Impact factor: 2.503

10.  Prognostic value of p27Kip1 expression in Basaloid Squamous Cell Carcinoma of the larynx.

Authors:  Grazia Salerno; Dolores Di Vizio; Stefania Staibano; Giampiero Mottola; Giuseppe Quaremba; Massimo Mascolo; Vieri Galli; Gaetano De Rosa; Luigi Insabato
Journal:  BMC Cancer       Date:  2006-06-01       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.